---
title: "Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296911087.md"
description: "Benzinga highlights analyst ratings for three high-dividend healthcare stocks: Perrigo (PRGO), Pfizer (PFE), and Bristol-Myers Squibb (BMY). Accurate analysts adjusted price targets, with PRGO yielding 8.13%, PFE 6.15%, and BMY 3.75%. Recent developments include Perrigo's strong Q2 results, Pfizer's EMA validation of a Lyme disease vaccine candidate, and FDA accelerated approval for BMY's Zenbexus for multiple myeloma."
datetime: "2026-08-25T11:39:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296911087.md)
  - [en](https://longbridge.com/en/news/296911087.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296911087.md)
generator: "portal-rs"
---

# Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

### **Perrigo Company PLC (NYSE:PRGO)**

-   **Dividend Yield:** 8.13%
-   **Canaccord Genuity** analyst Susan Anderson maintained a Buy rating and cut the price target from $20 to $17 on Feb. 27, 2026. This analyst has an accuracy rate of 56%.
-   **JP Morgan** analyst Chris Scott maintained a Neutral rating and slashed the price target from $20 to $18 on Dec. 15, 2025. This analyst has an accuracy rate of 65%.
-   **Recent News:** On Aug. 5, Perrigo reported better-than-expected second-quarter financial results and affirmed its FY26 adjusted EPS guidance above estimates.
-   Benzinga Pro’s real-time newsfeed alerted to latest PRGO news.

### **Pfizer Inc (NYSE:PFE)**

-   **Dividend Yield:** 6.15%
-   **Guggenheim** analyst Vamil Divan maintained a Buy rating and cut the price target from $35 to $31 on Aug. 7, 2026. This analyst has an accuracy rate of 79%.
-   **BMO Capital** analyst Evan David Seigerman maintained an Outperform rating and slashed the price target from $34 to $30 on July 13, 2026. This analyst has an accuracy rate of 58%.
-   **Recent News:** On Aug. 14, **Valneva SE** (NASDAQ:VALN) and its partner Pfizer announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.
-   Benzinga Pro’s real-time newsfeed alerted to latest PFE news

### **Bristol-Myers Squibb Co (NYSE:BMY)**

-   **Dividend Yield:** 3.75%
-   **Argus Research** analyst Jasper Hellweg upgraded the stock from Hold to Buy with a price target of $75 on Aug. 5, 2026. This analyst has an accuracy rate of 55%.
-   **Citigroup** analyst Geoff Meacham maintained a Neutral rating and increased the price target from $66 to $70 on Aug. 3, 2026. This analyst has an accuracy rate of 75%
-   **Recent News:** On Aug. 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) for adult patients with multiple myeloma.
-   Benzinga Pro’s real-time newsfeed alerted to latest BMY news

*Photo via Shutterstock*

### Related Stocks

- [PRGO.US](https://longbridge.com/en/quote/PRGO.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [VALN.US](https://longbridge.com/en/quote/VALN.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares](https://longbridge.com/en/news/296941366.md)
- [17,077 Shares in Bristol Myers Squibb Company $BMY Purchased by Avaii Wealth Management LLC](https://longbridge.com/en/news/296315075.md)
- [LaSalle St. Investment Advisors LLC Takes $1.12 Million Position in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/296603017.md)
- [Vise Technologies Inc. Purchases 96,548 Shares of Pfizer Inc. $PFE](https://longbridge.com/en/news/296698057.md)
- [Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims](https://longbridge.com/en/news/296430772.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**